Press Release Archive
Press Releases
April 2020
04.28.2020 Finance PFIZER REPORTS FIRST-QUARTER 2020 RESULTS 04.23.2020 Finance Pfizer Hosts Virtual-Only Annual Meeting of Shareholders 04.22.2020 Partnerships FoRx Therapeutics AG Raises EUR 10 Million Seed Round to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer 04.22.2020 Research Vaccines BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates 04.20.2020 Partnerships Valneva Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15 04.09.2020 Covid-19 Partnerships Vaccines Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development 04.09.2020 Covid-19 Vaccines Pfizer Advances Battle Against COVID-19 on Multiple Fronts 04.09.2020 EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma 04.08.2020 Medicines U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy 04.07.2020 Finance Pfizer to Hold Virtual-Only 2020 Annual Meeting of Shareholders 04.06.2020 Responsibility Pfizer and The Pfizer Foundation Donate $40 Million in Charitable Grants, Expand Product Access and Mobilize Colleagues to Combat COVID-19 Pandemic 04.02.2020 Medicines Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.